29823-18-5

Basic information

• Product Name: Ethyl 7-bromoheptanoate
• Synonyms: Ethyl 7-bromoheptanoate 97%;CHEMPACIFIC 43805;ETHYL W-BROMOHEPTANOATE;ETHYL 7-BROMOHEPTANOATE;7-BROMOHEPTANOIC ACID ETHYL ESTER;7-BROMOHEPTANOIC ACID ETHYL ESTER 96+%;Ai3-36604;Einecs 249-883-6
• CAS NO: 29823-18-5
• Molecular Formula: C₉H₁₇BrO₂
• Molecular Weight: 237.13
• EINECS: 249-883-6
• Product Categories: Pharmaceutical Intermediates;C8 to C9;Carbonyl Compounds;Esters
• Mol File: 29823-18-5.mol
• Article Data: 10

Chemical Properties

• Melting Point: 29 °C(lit.)
• Boiling Point: 112 °C5 mm Hg(lit.)
• Flash Point: >230 °F
• Appearance: /
• Density: 1.217 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.0241mmHg at 25°C
• Refractive Index: n20/D 1.459(lit.)
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Ethyl 7-bromoheptanoate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 7-bromoheptanoate(29823-18-5)
• EPA Substance Registry System: Ethyl 7-bromoheptanoate(29823-18-5)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 29823-18-5(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
Ethyl 7-bromoheptanoate is used as a starting material for the synthesis of benzyl 7-iodoheptanoate, which is an important intermediate in the production of various organic compounds.
Used in Pharmaceutical Research:
Ethyl 7-bromoheptanoate is used as one of the reactants in the synthesis of diethyl 7,7′-(2,5-diiodo-1,4-phenylene)bis(oxy)diheptanoate, a compound that may have potential applications in the pharmaceutical industry.
Used in the Synthesis of Carnitine-Derived Nitrones:
Ethyl 7-bromoheptanoate is employed as one of the reagents in the synthesis of CarnDOD-7C, a carnitine-derived nitrone that has potential applications in the field of neuroprotection and the treatment of neurodegenerative diseases.
Used as an Alkylating Agent:
Ethyl 7-bromoheptanoate is used as an alkylating agent in the alkylation of ethyl 3-oxoglutarate to form 2-(6-ethoxycarbonylhexyl)-3-oxoglutarate, a key step in the synthesis of various organic compounds.
Used in the Synthesis of 1-Substituted Cyclopentadienes:
Ethyl 7-bromoheptanoate is utilized in the synthesis of 1-substituted cyclopentadienes by alkylating lithium cyclopentadienide, which are important intermediates in the production of various organic compounds and materials.

InChI:InChI=1/C9H17BrO2/c1-2-12-9(11)7-5-3-4-6-8-10/h2-8H2,1H3

Upstream product

• 64-17-5 ethanol 
• 30515-28-7 7-bromoheptanoic acid 
• 6149-48-0 ethyl 7-hydroxyheptanoate 
• 20965-27-9 7-bromo-heptanonitrile 
• 111-24-0 1,5-dibromo-pentane 
• 505-48-6 octane-1,8-dioic acid 
• 96251-91-1 ethyl (E)-7-hydroxyhept-2-enoate 
• 694-54-2 tetrahydro-2H-2-pyranol 
• 14113-01-0 Ethyl hydrogen suberate 

Downstream Products

• 54635-96-0 8-Phenyl-9-oxodecansaeureethylester 
• 105728-05-0 7-(3-Formyl-4-nitro-phenoxy)-heptanoic acid ethyl ester 
• 1004305-56-9 7-[4-(benzyloxy)phenoxy]heptanoic acid ethyl ester 
• 79496-25-6 ethyl 3-benzylidene-2-(6-ethoxycarbonylhexyl)carbazate 
• 91303-97-8 7-[2-(1H-imidazol-1-yl)-1-[[(4-methoxyphenyl)methoxy]methyl]ethoxy]heptanoic acid 
• 96120-80-8 7-[2-Bromo-5-(2,4-diamino-pyrimidin-5-ylmethyl)-3-methoxy-phenoxy]-heptanoic acid ethyl ester 
• 30515-28-7 7-bromoheptanoic acid 
• 26559-57-9 ethyl 7-(methyl(phenyl)amino)heptanoate 
• 852575-36-1 7-[(2,6-dimethylphenyl)amino]heptanoic acid ethyl ester 
• 112665-41-5 ethyl 7-oxo-7-phenylheptanoate 
• 1026433-05-5 7-[3-(2,4-diamino-pyrimidin-5-ylmethyl)-4-methoxy-phenoxy]-heptanoic acid ethyl ester 
• 57267-45-5 (7-ethoxy-7-oxoheptyl)-triphenylphosphonium bromide 
• 1832-11-7 2-Aethoxycarbonyl-2-phenyl-azelainsaeure-diaethylester 
• 54636-18-9 8-(3-Acetoxymethyl-benzyl)-9-oxo-8-phenyl-decanoic acid 

Relevant articles and documents

Process for preparing azelaic acid

A process for preparing azelaic acid is disclosed. In particular, the process for preparing azelaic acid is an ozone free process. The process for preparing azelaic acid comprises a step of decarboxylation of tetra-carboxylic acid in the presence of a organic sulfonic acid.

COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS

The disclosure features amino lipids and compositions involving the same. Nanoparticle compositions include an amino lipid as well as additional lipids such as phospholipids, structural lipids, PEG lipids, or a combination thereof. Nanoparticle compositions further including therapeutic and/or prophylactic agents such as RNA are useful in the delivery of therapeutic and/or prophylactic agents to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.

COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS

The disclosure features amino lipids and compositions involving the same. Nanoparticle compositions include an amino lipid as well as additional lipids such as phospholipids, structural lipids, PEG lipids, or a combination thereof. Nanoparticle compositions further including therapeutic and/or prophylactic agents such as RNA are useful in the delivery of therapeutic and/or prophylactic agents to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.

Synthesis and Characterization of Novel Acyl-Glycine Inhibitors of GlyT2

It has been demonstrated previously that the endogenous compound N-arachidonyl-glycine inhibits the glycine transporter GlyT2, stimulates glycinergic neurotransmission, and provides analgesia in animal models of neuropathic and inflammatory pain. However, it is a relatively weak inhibitor with an IC50 of 9 μM and is subject to oxidation via cyclooxygenase, limiting its therapeutic value. In this paper we describe the synthesis and testing of a novel series of monounsaturated C18 and C16 acyl-glycine molecules as inhibitors of the glycine transporter GlyT2. We demonstrate that they are up to 28 fold more potent that N-arachidonyl-glycine with no activity at the closely related GlyT1 transporter at concentrations up to 30 μM. This novel class of compounds show considerable promise as a first generation of GlyT2 transport inhibitors.

The value of 2JP–CO as a diagnostic parameter for the structure and thermal reactivity of carbonyl-stabilised phosphonium ylides

A survey of 20 carbonyl-stabilised phosphonium ylides with recently reported X-ray structures shows a strong correlation between the C[dbnd]P to C[dbnd]O torsion angle and the value of 2JP–CO, with high values being associated with an anti configuration and low with syn. Seven new X-ray structural determinations are reported, several for types of ylide not crystallographically characterised before, and these also conform to this pattern. The value of 2JP–CO is then correlated with whether or not thermal extrusion of Ph3PO occurs to give alkynes for over 200 ylides and an empirical rule developed that the extrusion never occurs for ylides where this value is > 11 Hz. This is used to rationalise the anomalous behaviour of some trioxo ylides and cyclic ylides, two of which afford cycloalkynes, isolated after rearrangement as the isomeric 1,3-dienes. The rule also holds for a family of novel highly fluorinated ylides which afford fluorinated alkynes in good yield upon flash vacuum pyrolysis.

Iron-catalyzed borylation of alkyl, allyl, and aryl halides: Isolation of an iron(I) boryl complex

Activation of B2pin2 with tBuLi facilitates the Fe-catalyzed borylation of alkyl, allyl, benzyl, and aryl halides via the formation of Li[B2pin2(tBu)] (1). The reaction of 1 with a representative iron phosphine precatalyst generates the unique iron(I) boryl complex [Fe(Bpin)(dpbz)2] (2).

Synthesis of 7-triazole-substituted camptothecin via click chemistry and evaluation of in vitro antitumor activity

Camptothecin (CPT) is a natural topoisomerase I inhibitor with powerful antineoplastic activity against colorectal, breast, lung and ovarian cancers. To discover more potent antitumor agents, a series of new CPT derivatives were synthesized utilizing click chemistry. All compounds were assessed for cytotoxicity against A549, HCT-116, HT-29, LoVo, MDA-MB-231 cell lines, and some compounds exhibited good in vitro potency. Furthermore, all compounds kept or enhanced Topo I inhibition. A series of novel 7-triazole substituted camptothecin via click chemistry was designed, synthesized, and evaluated for their in vitro antitumor activity. Copyright

OMEGA-3 ANALOGUES

The present invention relates to new fatty acid analogues and to their use in cancer therapy, including antimetastatic therapy.

Antiproliferative and antimigratory actions of synthetic long chain n-3 monounsaturated fatty acids in breast cancer cells that overexpress cyclooxygenase-2

Cyclooxygenase-2 (COX-2) is overexpressed in many human cancers and converts the n-6 polyunsaturated fatty acid (PUFA) arachidonic acid to prostaglandin E2 (PGE2), which drives tumorigenesis; in contrast, n-3 PUFA inhibit tumorigenesis. We tested the hypothesis that these antitumor actions of n-3 PUFA may involve the n-3 olefinic bond. n-3 Monounsaturated fatty acids (MUFAs) of chain length C16-C22 were synthesized and evaluated in MDA-MB-468 breast cancer cells that stably overexpressed COX-2 (MDA-COX-2 cells). Longer chain (C19-C22) n-3 MUFAs inhibited proliferation, activated apoptosis, decreased PGE2 formation, and decreased cell invasion; C16-C18 analogues were less active. Molecular modeling showed that interactions of Arg120, Tyr355, and several hydrophobic amino acid residues in the COX-2 active site with C19-C22 MUFA analogues were favored. Thus, longer-chain n-3 MUFAs may be prototypes of novel anticancer agents that decrease the formation of PGE2 in tumor cells that contain high levels of COX-2.

Titanium(III) mediated regiospecific reduction of vinyl epoxides

A highly regiospecific reduction of vinyl epoxides to allyl alcohols with Cp2TiCl is described.